Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne (NASDAQ: TECH) reported its Q4 and full fiscal year 2024 results. Q4 organic revenue increased by 1% (2% reported) to $306.1 million, while full-year organic revenue grew 1% (2% reported) to $1.2 billion. Q4 GAAP EPS was $0.25, down from $0.47 a year ago, and adjusted EPS was $0.49, compared to $0.55 last year. Full-year GAAP EPS decreased to $1.05 from $1.76, and adjusted EPS fell to $1.77 from $1.99. The Diagnostics & Genomics segment showed strong performance with 9% organic growth in Q4 and 6% for the full year. Cash flow from operations increased by 18% to $299.0 million for fiscal 2024. The company noted stabilization in biopharma and China markets, with continued focus on profitability resulting in a 33.5% adjusted operating margin in Q4.

Bio-Techne (NASDAQ: TECH) has announced the launch of the Leo™ System, a next-generation Simple Western™ instrument. This advanced system offers:

• Higher throughput: Process up to 100 samples in a single 3-hour run
• 4-times larger experimental size compared to current systems
• Enhanced quantitative capabilities for rigorous bioanalytical methods
• Improved data quality and speed over traditional western blotting

The Leo System enables ELISA-like protein quantitation with western blotting specificity, opening up new applications in drug development, clinical biomarkers, and vaccine research. Bio-Techne expects to begin shipping the Leo System in 2025.

Bio-Techne (NASDAQ: TECH) has announced its participation in Spear Bio's $45 million Series A funding round. Spear Bio, founded in 2021, is developing ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar levels from sub-microliter sample volumes. Their proprietary Successive Proximity Extension Amplification Reaction (SPEAR) technology offers significant advantages over traditional immunoassay and next-gen proteomic technologies.

The funding will accelerate Spear Bio's product development and scale its in-house manufacturing capacity. The company's initial offering will focus on key biomarkers supporting translational research in Alzheimer's disease. Bio-Techne's CEO, Kim Kelderman, expressed excitement about the investment, highlighting the potential for early diagnosis of neurodegenerative diseases using Spear Bio's technology.

Bio-Techne (NASDAQ: TECH) has announced a conference call and webcast scheduled for August 7, 2024, at 8:00 a.m. CDT to review their fourth quarter and fiscal 2024 financial results. Investors and interested parties can access the call via phone or webcast. For those unable to attend live, a recorded rebroadcast will be available from 11:00 a.m. CDT on August 7 until 11:00 p.m. CDT on September 7, 2024. This event provides an opportunity for stakeholders to gain insights into Bio-Techne's financial performance and future outlook.

Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will present at several upcoming investor conferences. These include the William Blair 44th Annual Growth Conference on June 4, 2024, the Jefferies Global Healthcare Conference on June 6, 2024, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024. Each presentation will be accessible via a live webcast on Bio-Techne's Investor Relations website.

Bio-Techne (NASDAQ: TECH) will showcase its MauriceFlex™ System at the 72nd ASMS Conference on Mass Spectrometry from June 2-6, 2024, in Anaheim, California.

The MauriceFlex System offers advanced imaged capillary isoelectric focusing (icIEF) solutions, including fractionation, and supports various mass spectrometric methods for protein characterization.

Highlights include a breakfast seminar on June 4th featuring Dr. Chris Heger and Dr. Sara Carillo discussing the system's applications, particularly in protein charge heterogeneity and cell and gene therapy.

Bio-Techne will also present seven posters detailing collaborations with industry leaders like Pfizer and 908 Devices, showcasing advancements in charge isoform characterization.

Will Geist, President of Protein Sciences, emphasized the system's unique capabilities and collaborative efforts at ASMS to advance life-saving therapies.

Visit Bio-Techne at Booth #161 and learn more at bio-techne.com/mauriceflex.

ScaleReady, in cooperation with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has unveiled a $20 million G-Rex® Grant Program aimed at advancing cell and gene therapy (CGT) development. The initiative offers up to $300,000 in G-Rex® devices, reagents, equipment, and support services to qualifying academic and commercial institutions. The program intends to reduce barriers to CGT innovation, enabling faster and more cost-effective development. Industry leaders emphasize the program's potential to enhance research timelines, streamline transitions to GMP manufacturing, and improve data quality for IND applications.

Bio-Techne (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will present at the 2024 Leerink Partners Healthcare Crossroads Conference.

The presentation is scheduled for May 29, 2024, at 8:40 a.m. CDT. Interested parties can access a live webcast of the presentation on Bio-Techne's Investor Relations website.

Bio-Techne (NASDAQ: TECH) and Regulus Therapeutics Inc. announced positive top-line results from the second cohort of their Phase 1b MAD study of RGLS8429 for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The collaboration, ongoing since 2020, utilizes Bio-Techne's Simple Western™ platforms and ExosomeDx CLIA laboratory for biomarker analysis. Regulus developed assays to measure polycystin 1 and 2 levels, key biomarkers in ADPKD, using Bio-Techne’s technology. This milestone highlights the clinical potential of RGLS8429 and advances the study, aiming to improve global healthcare with innovative therapeutics.